- Home
- SAFT vs PCRX Comparison
SAFT vs PCRX Comparison
Compare SAFT & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFT
- PCRX
- Stock Information
- Founded
- SAFT 1979
- PCRX 2006
- Country
- SAFT United States
- PCRX United States
- Employees
- SAFT N/A
- PCRX N/A
- Industry
- SAFT Property-Casualty Insurers
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SAFT Finance
- PCRX Health Care
- Exchange
- SAFT Nasdaq
- PCRX Nasdaq
- Market Cap
- SAFT 1.0B
- PCRX 1.2B
- IPO Year
- SAFT N/A
- PCRX 2011
- Fundamental
- Price
- SAFT $68.93
- PCRX $21.36
- Analyst Decision
- SAFT
- PCRX Buy
- Analyst Count
- SAFT 0
- PCRX 5
- Target Price
- SAFT N/A
- PCRX $32.40
- AVG Volume (30 Days)
- SAFT 62.4K
- PCRX 514.0K
- Earning Date
- SAFT 10-28-2025
- PCRX 10-31-2025
- Dividend Yield
- SAFT 5.34%
- PCRX N/A
- EPS Growth
- SAFT 65.99
- PCRX N/A
- EPS
- SAFT 5.73
- PCRX N/A
- Revenue
- SAFT $1,199,774,000.00
- PCRX $705,848,000.00
- Revenue This Year
- SAFT N/A
- PCRX $7.27
- Revenue Next Year
- SAFT N/A
- PCRX $10.18
- P/E Ratio
- SAFT $12.03
- PCRX N/A
- Revenue Growth
- SAFT 16.96
- PCRX 2.25
- 52 Week Low
- SAFT $67.82
- PCRX $16.00
- 52 Week High
- SAFT $90.00
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- SAFT 40.85
- PCRX 31.83
- Support Level
- SAFT $68.98
- PCRX $20.50
- Resistance Level
- SAFT $70.49
- PCRX $21.90
- Average True Range (ATR)
- SAFT 1.23
- PCRX 0.87
- MACD
- SAFT 0.07
- PCRX -0.10
- Stochastic Oscillator
- SAFT 41.57
- PCRX 40.96
About SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.